Regulatory Boehringer Ingelheim Pharmaceuticals Inc. / /
Event
FDA Phase / /
Facility
Allergy University of Nebraska Medical Center Samy Suissa / Clinical Epidemiology Lady Davis Research Institute / Harbor-UCLA Medical Center / Rehabilitation Clinical Trials Center Los Angeles Biomedical Research Institute / /
MedicalCondition
COPD / shortness of breath / emphysema / very severe COPD / chronic bronchitis / asthma / /
MedicalTreatment
Radiation / /
Organization
UCLA Medical Center / UCLA / Yale School / Centre for Clinical Epidemiology / Women’s Hospital / McGill University / Inhalation Spray United States Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee / Los Angeles Biomedical Research Institute / UCLA School of Medicine Medical / Critical Care / Sleep and Allergy University of Nebraska Medical Center Samy Suissa / Medicine Division / Harvard Medical School Institute / Clinical Epidemiology Lady Davis Research Institute / /
Person
Boehringer Ingelheim / Safety Bernd Disse / I. Rennard / Raymond Mak / Perspective Richard Casaburi / Efficacy Alan Hamilton / Richard Casaburi / Samy Suissa / /
Position
Director / Rehabilitation Clinical Trials Center / Director North America and Senior Vice President Medicine / Professor / Advisors / Director / COPD Enrolled patients representative / Physician / PhD Clinical Program Leader / Regional Medical Director / General / Professor of Biostatistics / Professor of Epidemiology / Biostatistics and Medicine / Therapeutic Area Head / /
CI-1 Striverdi® Respimat® (olodaterol) Inhalation Spray United States Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee